Global mRNA Cancer Vaccines and Therapeutics 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI03256509

Publication Date:

March 27, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global mRNA Cancer Vaccines and Therapeutics market size is predicted to grow from US$ 227 million in 2025 to US$ 669 million in 2031; it is expected to grow at a CAGR of 19.7% from 2025 to 2031.
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
North America is the largest mRNA Cancer Vaccines and Therapeutics market with about 69% market share. Europe is follower, accounting for about 28% market share.
The key players are Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology etc. Top 3 companies occupied about 82% market share.
The 鈥渕RNA Cancer Vaccines and Therapeutics Industry Forecast鈥� looks at past sales and reviews total world mRNA Cancer Vaccines and Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected mRNA Cancer Vaccines and Therapeutics sales for 2025 through 2031. With mRNA Cancer Vaccines and Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world mRNA Cancer Vaccines and Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global mRNA Cancer Vaccines and Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on mRNA Cancer Vaccines and Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global mRNA Cancer Vaccines and Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for mRNA Cancer Vaccines and Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global mRNA Cancer Vaccines and Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of mRNA Cancer Vaccines and Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Adeno Carcinomas
Mucinous Carcinomas
Adenosquamous Carcinomas
Segmentation by Application:
Infectious Disease
Cancer
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size (2020-2031)
2.1.2 mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for mRNA Cancer Vaccines and Therapeutics by Country/Region (2020, 2024 & 2031)
2.2 mRNA Cancer Vaccines and Therapeutics Segment by Type
2.2.1 Adeno Carcinomas
2.2.2 Mucinous Carcinomas
2.2.3 Adenosquamous Carcinomas
2.3 mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size by Type
2.3.1 mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 mRNA Cancer Vaccines and Therapeutics Segment by Application
2.4.1 Infectious Disease
2.4.2 Cancer
2.4.3 Others
2.5 mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size by Application
2.5.1 mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size by Player
3.1 mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global mRNA Cancer Vaccines and Therapeutics Revenue by Player (2020-2025)
3.1.2 Global mRNA Cancer Vaccines and Therapeutics Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global mRNA Cancer Vaccines and Therapeutics Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 mRNA Cancer Vaccines and Therapeutics by Region
4.1 mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size by Region (2020-2025)
4.2 Global mRNA Cancer Vaccines and Therapeutics Annual Revenue by Country/Region (2020-2025)
4.3 Americas mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size Growth (2020-2025)
4.4 APAC mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size Growth (2020-2025)
4.5 Europe mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size by Country (2020-2025)
5.2 Americas mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size by Type (2020-2025)
5.3 Americas mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size by Region (2020-2025)
6.2 APAC mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size by Type (2020-2025)
6.3 APAC mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size by Country (2020-2025)
7.2 Europe mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size by Type (2020-2025)
7.3 Europe mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa mRNA Cancer Vaccines and Therapeutics by Region (2020-2025)
8.2 Middle East & Africa mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa mRNA Cancer Vaccines and Therapeutics 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global mRNA Cancer Vaccines and Therapeutics 麻豆原创 Forecast
10.1 Global mRNA Cancer Vaccines and Therapeutics Forecast by Region (2026-2031)
10.1.1 Global mRNA Cancer Vaccines and Therapeutics Forecast by Region (2026-2031)
10.1.2 Americas mRNA Cancer Vaccines and Therapeutics Forecast
10.1.3 APAC mRNA Cancer Vaccines and Therapeutics Forecast
10.1.4 Europe mRNA Cancer Vaccines and Therapeutics Forecast
10.1.5 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Forecast
10.2 Americas mRNA Cancer Vaccines and Therapeutics Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.2.2 Canada 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.2.3 Mexico 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.2.4 Brazil 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.3 APAC mRNA Cancer Vaccines and Therapeutics Forecast by Region (2026-2031)
10.3.1 China mRNA Cancer Vaccines and Therapeutics 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.3.3 Korea 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.3.4 Southeast Asia 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.3.5 India 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.3.6 Australia 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.4 Europe mRNA Cancer Vaccines and Therapeutics Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.4.2 France 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.4.3 UK 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.4.4 Italy 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.4.5 Russia 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.5 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.5.2 South Africa 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.5.3 Israel 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.5.4 Turkey 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
10.6 Global mRNA Cancer Vaccines and Therapeutics Forecast by Type (2026-2031)
10.7 Global mRNA Cancer Vaccines and Therapeutics Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 mRNA Cancer Vaccines and Therapeutics Forecast
11 Key Players Analysis
11.1 Moderna Therapeutics
11.1.1 Moderna Therapeutics Company Information
11.1.2 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product Offered
11.1.3 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Moderna Therapeutics Main Business Overview
11.1.5 Moderna Therapeutics Latest Developments
11.2 CureVac
11.2.1 CureVac Company Information
11.2.2 CureVac mRNA Cancer Vaccines and Therapeutics Product Offered
11.2.3 CureVac mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 CureVac Main Business Overview
11.2.5 CureVac Latest Developments
11.3 Translate Bio
11.3.1 Translate Bio Company Information
11.3.2 Translate Bio mRNA Cancer Vaccines and Therapeutics Product Offered
11.3.3 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Translate Bio Main Business Overview
11.3.5 Translate Bio Latest Developments
11.4 BioNTech
11.4.1 BioNTech Company Information
11.4.2 BioNTech mRNA Cancer Vaccines and Therapeutics Product Offered
11.4.3 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 BioNTech Main Business Overview
11.4.5 BioNTech Latest Developments
11.5 Sangamo Therapeutics
11.5.1 Sangamo Therapeutics Company Information
11.5.2 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product Offered
11.5.3 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Sangamo Therapeutics Main Business Overview
11.5.5 Sangamo Therapeutics Latest Developments
11.6 Argos Therapeutics
11.6.1 Argos Therapeutics Company Information
11.6.2 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product Offered
11.6.3 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Argos Therapeutics Main Business Overview
11.6.5 Argos Therapeutics Latest Developments
11.7 In-Cell-Art
11.7.1 In-Cell-Art Company Information
11.7.2 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product Offered
11.7.3 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 In-Cell-Art Main Business Overview
11.7.5 In-Cell-Art Latest Developments
11.8 eTheRNA
11.8.1 eTheRNA Company Information
11.8.2 eTheRNA mRNA Cancer Vaccines and Therapeutics Product Offered
11.8.3 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 eTheRNA Main Business Overview
11.8.5 eTheRNA Latest Developments
11.9 Ethris
11.9.1 Ethris Company Information
11.9.2 Ethris mRNA Cancer Vaccines and Therapeutics Product Offered
11.9.3 Ethris mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Ethris Main Business Overview
11.9.5 Ethris Latest Developments
11.10 Tiba Biotechnology
11.10.1 Tiba Biotechnology Company Information
11.10.2 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product Offered
11.10.3 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Tiba Biotechnology Main Business Overview
11.10.5 Tiba Biotechnology Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.